Cepheid Inc (CPHD) 34.26 $CPHD Shares of CPHD Up 21.8%

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:12 PM

Cepheid Inc (CPHD) 34.26 $CPHD

Shares of CPHD Up 21.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 24, 1:47PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 21.85% as of today's recent price of $36.25.
CPHD: 34.26 (unch)

Interesting CPHD Put And Call Options For October 21st
DividendChannel.com - Mon Aug 22, 10:46AM CDT
Investors in Cepheid saw new options begin trading today, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPHD options chain for the new October 21st contracts and identified one put and...
CPHD: 34.26 (unch)

Moving Average Crossover Alert: Cepheid (CPHD)
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:31AM CDT
Cepheid (CPHD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
CPHD: 34.26 (unch)

21.0% Return Seen to Date on SmarTrend Cepheid Call (CPHD)
Comtex SmarTrend(R) - Wed Aug 17, 1:15AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 21.01% as of today's recent price of $36.00.
CPHD: 34.26 (unch)

Cepheid Shares Up 24.2% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Tue Aug 09, 1:45PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 24.17% as of today's recent price of $36.94.
CPHD: 34.26 (unch)

Global Enteric Disease Testing Market 2016-2020 - Key Vendors are Alere, bioMrieux, Cepheid & DiaSorin - Research and Markets
BusinessWire - Tue Aug 09, 9:55AM CDT
Research and Markets has announced the addition of the "Global Enteric Disease Testing Market 2016-2020" report to their offering.
CPHD: 34.26 (unch)

Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Thu Aug 04, 3:05PM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
CPHD: 34.26 (unch)

Henry Schein (HSIC) Tops Q2 Earnings, Sales; Slashes View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:46PM CDT
Henry Schein (HSIC) ended second quarter of 2016 on an impressive note, squarely beating the Zacks Consensus Estimate.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), HSIC: 164.25 (+1.27)

AmSurg (AMSG) Lags Q2 Earnings & Sales; Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:28AM CDT
AmSurg (AMSG) ended the second quarter of 2016 on a disappointing note, with quarterly numbers missing the Zacks Consensus Estimate on both fronts.
AMSG: 67.18 (+1.78), BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)

Masimo (MASI) Beats Q2 Earnings, Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Masimo Corp reported earnings of 49 cents per share that beat the Zacks Consensus Estimate by 8 cents.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), MLAB: 112.83 (-0.55)

Fresenius Medical (FMS) Q2 Earnings & Sales Lag Estimates
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:56AM CDT
Fresenius Medical Care (FMS) reported adjusted earnings of 48 cents per American Depositary Share (ADS) in the second quarter of 2016, missing the Zacks Consensus Estimate by a penny.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), FMS: 44.67 (+1.07)

Genomic Health (GHDX) Q2 Loss Narrows Y/Y, Sales Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 2:11PM CDT
Genomic's (GHDX) second-quarter bottom line outcome improved year over year and came in line with the Zacks Consensus Estimate
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), GHDX: 27.05 (+0.38)

Wright Medical (WMGI) Posts Narrower Loss in Q2, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 1:52PM CDT
Wright Medical Group N.V. (WMGI) reported adjusted loss of 18 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 32 cents.
BABY: 40.36 (+0.65), WMGI: 24.65 (+0.04), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)

DexCom (DXCM) Q2 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:18AM CDT
DexCom Inc. (DXCM) reported loss of 24 cents per share in the second quarter of 2016, much wider than the Zacks Consensus Estimate of a loss of 11 cents.
BABY: 40.36 (+0.65), DXCM: 92.01 (+0.30), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)

Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.69 (+0.26), CPHD: 34.26 (unch), LMNX: 21.01 (+0.08), MLAB: 112.83 (-0.55)

IDEXX (IDXX) Tops Q2 Earnings, Revenues, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:41AM CDT
IDEXX Laboratories Inc. (IDXX) reported second-quarter 2016 earnings per share (EPS) of 74 cents, up 23% year over year .
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), IDXX: 113.94 (+0.78)

Integer (ITGR) Misses on Q2 Earnings, Synergy View Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 4:05PM CDT
Integer (ITGR) reported adjusted earnings of 56 cents per share in the second quarter of 2016, which missed the Zacks Consensus Estimate of 74 cents.
MASI: 59.69 (+0.26), ITGR: 24.45 (+0.45), NVTR: 6.86 (+0.01), CPHD: 34.26 (unch)

Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), HAE: 37.66 (+0.34), CPHD: 34.26 (unch)

Cepheid Up 20.5% Since SmarTrend Uptrend Call (CPHD)
Comtex SmarTrend(R) - Tue Aug 02, 1:55PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 1 month, Cepheid has returned 20.50% as of today's recent price of $35.85.
CPHD: 34.26 (unch)

Cepheid (CPHD) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:33AM CDT
Cepheid (CPHD) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA.
CPHD: 34.26 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fast Renovations Could Save Homeowners Big Bucks

Speed Matters in Renovation Projects You ever been locked in that eternal waiting game with a renovation project? It's a killer for the wallet. Chapter Renovation's digging into this mess, showing how dragging out a project can cost homeowners plenty more than they bargained for. They've been pushing an average completion time of 38 weeks. Compare that to the chilling...

UN Forum Unleashes LatAm CEO Coalition for Action

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Lululemon Faces Lawsuit Over Alleged Fraudulent Reporting

What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...

TORM's Q3 Results Point to Strength Amid Global Chaos

TORM Navigates Chaotic Waters With Impressive Earnings Alright, TORM's catching my eye here amidst what seems like a global logistical mess. These folks are proving that chaos can indeed be lucrative. Cranking out robust numbers in Q3 2026, they've managed to steer through the murky oil trade waters carved by US-Iran tensions. We're seeing TORM's time charter equivalent...

Singtel, Ericsson Push 6G Healthcare to the Forefront

Breaking Ground in Healthcare Tech Ah, what’s cooking in Singapore? On a day like today, when the tech giants Singtel and Ericsson get chummy with National University Health System (NUHS), we're looking at the kind of healthcare advancements that read like science fiction. They’ve signed an MOU to launch the National University XG AI Centre (NXAC) – a mouthful,...

Exiger Lands $12M Deal with USAF for ICBM Insights

Exiger's New Partnership: A $12M Heavyweight Move The Air Force isn’t about to let its guard down when it comes to those intercontinental ballistic missiles. Nope, the powers that be have decided it’s time to pump some serious dough into the chain that keeps those missiles ready to go, handing $12 million over to Exiger to light the path through the complex web of the...

Hyundai Pushes Hydrogen Boundaries at 2026 Expo

A Bold Step Into the Hydrogen Era Hyundai's really stepping it up at the World Hydrogen Expo 2026. They're not just dipping their toes in the hydrogen pool—they're diving in headfirst, showing off integrated hydrogen solutions that are nothing short of ambitious. Hydrogen Production That's a Real Game Changer This ain't just talk. Hyundai's showcasing modular PEM...

Smartphone Durability: What Investors Need to Know

When a Drop Becomes a Cost-Benefit Analysis As someone who’s been around the block more times than I care to count, here’s a nugget for you: we rarely think about all the little things that could drill a hole in our pockets until they do. Take smartphones, the ubiquitous little beasts we carry everywhere. An accidental drop, one moment you’re butterfingering it in...

Minghui and ASKA Seal Major Licensing Deal for MHB018A

Breaking New Ground in Thyroid Eye Disease Treatment If there's one thing that keeps the biopharma world on its toes, it's the relentless pursuit of groundbreaking treatments. And folks, let me tell you, the latest tie-up between Minghui Pharmaceutical and ASKA Pharmaceutical has struck a chord. This union with MHB018A at its core might be one of those watershed moments...

New CMO Joins ARTHEx: Boosting Innovative RNA Focus

ARTHEx Biotech's Strategic Expansion Looks like ARTHEx Biotech is shaking things up with some strategic moves by bringing in Dr. Christian Freitag as their new Chief Medical Officer. Now, if you’re knee-deep in the biotech game, you'll know that having someone like Freitag onboard is akin to adding a star player to your lineup. The guy's got more than two decades of...